NOVA2

Across TCGA pan-cancer cohorts, NOVA2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of NOVA2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where NOVA2 RNA is repressed in tumor relative to normal tissue. In most cancer types NOVA2 is over-expressed in tumor, although a few such as LUAD and KIRP show the opposite, repressed pattern.

LUAD, KIRC, and KIRP are the cancer types where NOVA2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NOVA2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−2.006	<.001	11	view →
KIRC	Female	All	+1.023	<.001	11	view →
KIRP	Male	All	−1.139	<.001	9	view →
LUSC	Female	II,III,IV	−2.174	<.001	8	view →
LIHC	Female	All	+0.499	<.001	8	view →
KICH	Male	All	−0.743	<.001	7	view →
HNSC	Female	III,IV	+0.701	<.001	7	view →
UCEC	All	All	−1.294	<.001	6	view →
BRCA	All	III,IV	−0.943	<.001	6	view →
STAD	Male	II,III,IV	+0.539	.003	5	view →
THCA	Male	IV	−0.783	.031	3	view →
CHOL	All	All	+0.619	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

NOVA2–LUAD

Open the LUAD breakdown →